Research programme: antibody-drug conjugate therapeutics - CytomX/ImmunoGenAlternative Names: CX-2009; Probody™-drug conjugates - CytomX/ImmunoGen
Latest Information Update: 11 May 2016
At a glance
- Originator CytomX Therapeutics; ImmunoGen
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Cell death stimulants; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer